Clinical Trial Update: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial is evaluating APG2575 as both a single agent and in combination therapy for relapsed/refractory chronic lymphocytic leukemia and small lymphocy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• APG2575

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: RECRUITING